http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 26 Aug 2026 19:24:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Estrella+Immunopharma%2C++++For%3A+Aug+25++Filed+by%3A+Liu+Cheng/26983198.html si-local-file:///var/storage/secattach/20260826/26983198.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Estrella+Immunopharma%2C++++For%3A+Aug+25++Filed+by%3A+Liu+Cheng/26983198.html Wed, 26 Aug 2026 19:24:00 -0400 ESLA O.52433315 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Estrella+Immunopharma%2C++++For%3A+Aug+25++Filed+by%3A+Liu+Cheng/26983198.html si-local-file:///var/storage/secattach/20260826/26983198.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Estrella+Immunopharma%2C++++For%3A+Aug+25++Filed+by%3A+Liu+Cheng/26983198.html Wed, 26 Aug 2026 19:24:00 -0400 ESLA O.52433315 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Estrella+Immunopharma%2C++++For%3A+Aug+18++Filed+by%3A+Xu+Jiandong/26976165.html si-local-file:///var/storage/secattach/20260825/26976165.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Estrella+Immunopharma%2C++++For%3A+Aug+18++Filed+by%3A+Xu+Jiandong/26976165.html Tue, 25 Aug 2026 21:56:00 -0400 ESLA O.52433315 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Estrella+Immunopharma%2C++++For%3A+Aug+18++Filed+by%3A+Xu+Jiandong/26976165.html si-local-file:///var/storage/secattach/20260825/26976165.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Estrella+Immunopharma%2C++++For%3A+Aug+18++Filed+by%3A+Xu+Jiandong/26976165.html Tue, 25 Aug 2026 21:56:00 -0400 ESLA O.52433315 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Estrella+Immunopharma%2C++++For%3A+Aug+17/26962299.html si-local-file:///var/storage/secattach/20260821/26962299.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Estrella+Immunopharma%2C++++For%3A+Aug+17/26962299.html Fri, 21 Aug 2026 17:00:00 -0400 ESLA O.52433315 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Estrella+Immunopharma%2C++++For%3A+Aug+17/26962299.html si-local-file:///var/storage/secattach/20260821/26962299.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Estrella+Immunopharma%2C++++For%3A+Aug+17/26962299.html Fri, 21 Aug 2026 17:00:00 -0400 ESLA O.52433315 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Estrella+Immunopharma%2C+++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26926195.html si-local-file:///var/storage/secattach/20260814/26926195.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Estrella+Immunopharma%2C+++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26926195.html Fri, 14 Aug 2026 10:12:00 -0400 ESLA O.52433315 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Estrella+Immunopharma%2C+++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26926195.html si-local-file:///var/storage/secattach/20260814/26926195.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Estrella+Immunopharma%2C+++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26926195.html Fri, 14 Aug 2026 10:12:00 -0400 ESLA O.52433315 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Estrella+Immunopharma%2C++++For%3A+Jun+30/26922525.html si-local-file:///var/storage/secattach/20260813/26922525.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Estrella+Immunopharma%2C++++For%3A+Jun+30/26922525.html Thu, 13 Aug 2026 17:01:00 -0400 ESLA O.52433315 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Estrella+Immunopharma%2C++++For%3A+Jun+30/26922525.html si-local-file:///var/storage/secattach/20260813/26922525.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Estrella+Immunopharma%2C++++For%3A+Jun+30/26922525.html Thu, 13 Aug 2026 17:01:00 -0400 ESLA O.52433315 http://www.streetinsider.com/Corporate+News/Estrella+Immunopharma+adds+fourth+site+to+lymphoma+trial/26901795.html <p>Estrella Immunopharma, Inc. (NASDAQ: ESLA) has activated University Hospitals Cleveland Medical Center as the fourth clinical site for its STARLIGHT-1 Phase I/II trial evaluating EB103, a CD19-targeted T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.</p><p>University Hospitals Cleveland Medical Center is an affiliated teaching hospital of Case Western Reserve University School of Medicine. The site is expected to begin screening and enrolling patients following the completion of site initiation activities.</p><p>The ongoing expansion phase of the trial is designed as a multi-center, open-label study evaluating the safety and efficacy of EB103 at the recommended Phase II dose in patients http://www.streetinsider.com/Corporate+News/Estrella+Immunopharma+adds+fourth+site+to+lymphoma+trial/26901795.html Tue, 11 Aug 2026 08:01:01 -0400 ESLA http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Activates+University+Hospitals+Cleveland+Medical+Center+as+Fourth+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26901687.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a fourth clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). The new site, University Hospitals Cleveland (UH Cleveland) Medical Center, an affiliated teaching hospital of Case Western Reserve University School of Medicine, is expected to begin screening and enrolling patients following completion of http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Activates+University+Hospitals+Cleveland+Medical+Center+as+Fourth+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26901687.html Tue, 11 Aug 2026 08:00:00 -0400 A.23318087 A.33151435 A.50214643 ESLA O.02147044 O.20409024 O.35847762 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Activates+University+Hospitals+Cleveland+Medical+Center+as+Fourth+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26901687.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a fourth clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). The new site, University Hospitals Cleveland (UH Cleveland) Medical Center, an affiliated teaching hospital of Case Western Reserve University School of Medicine, is expected to begin screening and enrolling patients following completion of http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Activates+University+Hospitals+Cleveland+Medical+Center+as+Fourth+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26901687.html Tue, 11 Aug 2026 08:00:00 -0400 A.23318087 A.33151435 A.50214643 ESLA O.02147044 O.20409024 O.35847762 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Activates+University+Hospitals+Cleveland+Medical+Center+as+Fourth+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26901687.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a fourth clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). The new site, University Hospitals Cleveland (UH Cleveland) Medical Center, an affiliated teaching hospital of Case Western Reserve University School of Medicine, is expected to begin screening and enrolling patients following completion of http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Activates+University+Hospitals+Cleveland+Medical+Center+as+Fourth+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26901687.html Tue, 11 Aug 2026 08:00:00 -0400 A.23318087 A.33151435 A.50214643 ESLA O.02147044 O.20409024 O.35847762 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Activates+University+Hospitals+Cleveland+Medical+Center+as+Fourth+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26901687.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a fourth clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). The new site, University Hospitals Cleveland (UH Cleveland) Medical Center, an affiliated teaching hospital of Case Western Reserve University School of Medicine, is expected to begin screening and enrolling patients following completion of http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Activates+University+Hospitals+Cleveland+Medical+Center+as+Fourth+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26901687.html Tue, 11 Aug 2026 08:00:00 -0400 A.23318087 A.33151435 A.50214643 ESLA O.02147044 O.20409024 O.35847762 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Activates+University+Hospitals+Cleveland+Medical+Center+as+Fourth+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26901687.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a fourth clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). The new site, University Hospitals Cleveland (UH Cleveland) Medical Center, an affiliated teaching hospital of Case Western Reserve University School of Medicine, is expected to begin screening and enrolling patients following completion of http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Activates+University+Hospitals+Cleveland+Medical+Center+as+Fourth+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26901687.html Tue, 11 Aug 2026 08:00:00 -0400 A.23318087 A.33151435 A.50214643 ESLA O.02147044 O.20409024 O.35847762 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Activates+University+Hospitals+Cleveland+Medical+Center+as+Fourth+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26901687.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a fourth clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). The new site, University Hospitals Cleveland (UH Cleveland) Medical Center, an affiliated teaching hospital of Case Western Reserve University School of Medicine, is expected to begin screening and enrolling patients following completion of http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Activates+University+Hospitals+Cleveland+Medical+Center+as+Fourth+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26901687.html Tue, 11 Aug 2026 08:00:00 -0400 A.23318087 A.33151435 A.50214643 ESLA O.02147044 O.20409024 O.35847762 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Activates+University+Hospitals+Cleveland+Medical+Center+as+Fourth+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26901687.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a fourth clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). The new site, University Hospitals Cleveland (UH Cleveland) Medical Center, an affiliated teaching hospital of Case Western Reserve University School of Medicine, is expected to begin screening and enrolling patients following completion of http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Activates+University+Hospitals+Cleveland+Medical+Center+as+Fourth+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26901687.html Tue, 11 Aug 2026 08:00:00 -0400 A.23318087 A.33151435 A.50214643 ESLA O.02147044 O.20409024 O.35847762 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Activates+University+Hospitals+Cleveland+Medical+Center+as+Fourth+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26901687.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a fourth clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). The new site, University Hospitals Cleveland (UH Cleveland) Medical Center, an affiliated teaching hospital of Case Western Reserve University School of Medicine, is expected to begin screening and enrolling patients following completion of http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Activates+University+Hospitals+Cleveland+Medical+Center+as+Fourth+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26901687.html Tue, 11 Aug 2026 08:00:00 -0400 A.23318087 A.33151435 A.50214643 ESLA O.02147044 O.20409024 O.35847762 O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Activates+University+Hospitals+Cleveland+Medical+Center+as+Fourth+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26901687.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a fourth clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). The new site, University Hospitals Cleveland (UH Cleveland) Medical Center, an affiliated teaching hospital of Case Western Reserve University School of Medicine, is expected to begin screening and enrolling patients following completion of http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Activates+University+Hospitals+Cleveland+Medical+Center+as+Fourth+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26901687.html Tue, 11 Aug 2026 08:00:00 -0400 A.23318087 A.33151435 A.50214643 ESLA O.02147044 O.20409024 O.35847762 O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Activates+University+Hospitals+Cleveland+Medical+Center+as+Fourth+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26901687.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a fourth clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). The new site, University Hospitals Cleveland (UH Cleveland) Medical Center, an affiliated teaching hospital of Case Western Reserve University School of Medicine, is expected to begin screening and enrolling patients following completion of http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Activates+University+Hospitals+Cleveland+Medical+Center+as+Fourth+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26901687.html Tue, 11 Aug 2026 08:00:00 -0400 A.23318087 A.33151435 A.50214643 ESLA O.02147044 O.20409024 O.35847762 O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Activates+University+Hospitals+Cleveland+Medical+Center+as+Fourth+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26901687.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a fourth clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). The new site, University Hospitals Cleveland (UH Cleveland) Medical Center, an affiliated teaching hospital of Case Western Reserve University School of Medicine, is expected to begin screening and enrolling patients following completion of http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Activates+University+Hospitals+Cleveland+Medical+Center+as+Fourth+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26901687.html Tue, 11 Aug 2026 08:00:00 -0400 A.23318087 A.33151435 A.50214643 ESLA O.02147044 O.20409024 O.35847762 O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Activates+University+Hospitals+Cleveland+Medical+Center+as+Fourth+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26901687.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a fourth clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). The new site, University Hospitals Cleveland (UH Cleveland) Medical Center, an affiliated teaching hospital of Case Western Reserve University School of Medicine, is expected to begin screening and enrolling patients following completion of http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Activates+University+Hospitals+Cleveland+Medical+Center+as+Fourth+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26901687.html Tue, 11 Aug 2026 08:00:00 -0400 A.23318087 A.33151435 A.50214643 ESLA O.02147044 O.20409024 O.35847762 O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Activates+University+Hospitals+Cleveland+Medical+Center+as+Fourth+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26901687.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a fourth clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). The new site, University Hospitals Cleveland (UH Cleveland) Medical Center, an affiliated teaching hospital of Case Western Reserve University School of Medicine, is expected to begin screening and enrolling patients following completion of http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Activates+University+Hospitals+Cleveland+Medical+Center+as+Fourth+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26901687.html Tue, 11 Aug 2026 08:00:00 -0400 A.23318087 A.33151435 A.50214643 ESLA O.02147044 O.20409024 O.35847762 O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Activates+University+Hospitals+Cleveland+Medical+Center+as+Fourth+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26901687.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a fourth clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). The new site, University Hospitals Cleveland (UH Cleveland) Medical Center, an affiliated teaching hospital of Case Western Reserve University School of Medicine, is expected to begin screening and enrolling patients following completion of http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Activates+University+Hospitals+Cleveland+Medical+Center+as+Fourth+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26901687.html Tue, 11 Aug 2026 08:00:00 -0400 A.23318087 A.33151435 A.50214643 ESLA O.02147044 O.20409024 O.35847762 O.52433315